Stay up to date with the latest news in the pharmaceutical industry
Johnson & Johnson (J&J) and Elan have signed an agreement to research, develop and commercialise selective products for the treatment and prevention of neurodegenerative conditions including Alzheimer's disease.
03 July 2009